![]()
|
|
||||||||
J. Biol. Chem., Vol. 276, Issue 30, 27864-27872, July 27, 2001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the a Department of Genetics, University of Melbourne, b Howard Florey Institute, University of Melbourne, Parkville 3052, Australia, the d Department of Molecular Biology, Max Planck Institute for Biophysical Chemistry, Am Fassberg 11D-37077 Goettingen, Germany, the e Division of Biochemistry and Molecular Biology, John Curtin School of Medical Research, Australian National University, Canberra 2061, Australia, the f Department of Paediatrics, Tokyo Electric Power Company Hospital and Keio University School of Medicine, Tokyo 160-0016, Japan, the g Department of Paediatrics, Dokkyo University School of Medicine, Koshigaya Hospital, Koshigaya-shi, 343-8555, Japan, the h Incyte Genomics, 214 Cambridge Science Park, Milton Road, Cambridge CB4 0WA, United Kingdom, and i Prince Henry's Institute, Monash Medical Centre, Melbourne 3168, Victoria, Australia
Received for publication, February 9, 2001, and in revised form, March 20, 2001
| |
ABSTRACT |
|---|
|
|
|---|
Human mutations in the transcription factor
SOX9 cause campomelic dysplasia/autosomal sex
reversal. Here we identify and characterize two novel heterozygous
mutations, F154L and A158T, that substitute conserved "hydrophobic
core" amino acids of the high mobility group domain at positions
thought to stabilize SOX9 conformation. Circular dichroism studies
indicated that both mutations disrupt Campomelic dysplasia/autosomal sex reversal
(CD/SRA1)1 is a severe
skeletal malformation syndrome associated with XY male-to-female sex
reversal caused by mutations in the SOX9 gene (1, 2). CD/SRA1 is an autosomal dominant disorder characterized by
congenital bowing of the long bones and other skeletal malformations
(narrow ilia, hypoplastic ischiopubic rami, micrognathia, cleft palate, and retroglossia), absence of olfactory bulbs and tracts, heart and
renal malformations, hypoplastic lungs, narrow thoracic cage, defective
tracheobronchial cartilages, small scapulae, and delayed bone age and
psychomotor disorders (3, 4). In 75% of cases there is 46 XY
testicular dysgenesis (5). The phenotypic changes seen in CD/SRA1
patients correlate with sites of expression of SOX9 and
suggest SOX9 is essential for the normal development of many organs.
CD/SRA1 individuals are heterozygous resulting in haploinsufficiency of
SOX9; presumably a critical dose of SOX9 is required to switch on
appropriate genes during development. The present study reports the
identification in two CD patients with novel amino acid substitution
mutations, A154L and A158T in the HMG domain of SOX9, the latter in an
XY female. To understand the functional consequences of these
mutations, we attempted to correlate in vitro studies
addressing protein structure, DNA binding, DNA bending, and importin
recognition with in vivo studies of nuclear transport and
transcriptional activation in cultured cells.
SOX9 is a member of a large class of SOX (SRY-type HMG
BOX) transcription factors (6) related to the testis
determining factor SRY through their HMG domains that bind and bend DNA
in a sequence-specific manner (7, 8). Expression of these proteins in
certain cell types at specific stages of development appears to govern
cell fate decisions. Genes directly regulated by SOX9 have been
identified in testis and bone. SOX9 is specifically expressed within
testicular Sertoli cells following their differentiation from the
supporting cells in the embryonic gonadal ridge (9-11). The sex
reversal phenotype of human CD/SRA1 is entirely consistent with a
failure of early Sertoli cell differentiation since most sex-reversed
patients exhibit normal female phenotype (4). Although the
male-determining genes activated by SOX9 in Sertoli cells have not been
identified, SOX9 activates the expression of the anti-Müllerian
hormone gene (AMH), which leads to the regression of the
female reproductive tract (12, 13). SOX9 is also expressed at high
levels at all sites where cartilage is being laid down with expression
most abundant in mesenchymal condensation just prior to overt
chondrocyte differentiation (14, 15). Studies in chondrocyte cell lines
and ectopic expression of SOX9 in transgenic mice reveal that SOX9
activates Col2a1 gene, Col11a2, and possibly
aggrecan (16-22).
Clinical mutations in SOX9 resulting in CD/SRA1 include
splice acceptor/donor changes, missense, nonsense, translocation, and
frameshift mutations (4, 23-27). There appears to be no correlation
between mutation type or position and severity of the disease or
associated sex reversal, with the same mutation causing varying degrees
of gonadal dysgenesis (23). Together with the lack of polymorphisms in
the SOX9 gene, it appears that SOX9 is intolerant to
variation, perhaps acting at a high biochemical threshold which if not
reached, CD is manifest. Another possibility is that the genetic
background in which the mutant allele resides influences SOX9 activity.
The two major classes of mutations causing CD/SRA1 are amino acid
substitutions in the HMG domain and truncations or frameshifts that
alter the C-terminal domain of SOX9. Two highly conserved domains
located at the C terminus, the PQS domain and PQA domain, are required
for maximal transcriptional activation, and C-terminal deletions of
SOX9 from CD patients show reduced transactivation activity
(27). All known point missense in SOX9 occurs in the HMG
domain (Fig. 1), the majority of which have been examined biochemically
and show altered DNA binding compared with wild type, although there
are a few exceptions (23). For example, P170R in the HMG domain had
near wild type DNA binding and bending but altered DNA binding
specificity (27). A second SOX9 mutant, A119V, showed near wild type
DNA binding and bending (27) suggesting that other essential but
unknown biochemical activities of the SOX9 HMG domain may exist. These
results support a model where reduced HMG domain function will lead to
reduced transcriptional activation, although this correlation had not been investigated prior to this study, because previous studies on SOX9
missense mutations in CD/SRA1 have only investigated DNA binding and bending.
The HMG domain consists of three In this study, we examine the structure of the mutant HMG domains by
fluorescence spectroscopy and circular dichroism and their ability to
bind and bend DNA and to be recognized by importins as part of the
nuclear import process. We also examined the effect of these mutations
in cultured cells where we measured the ability of SOX9 to transport to
the nucleus and to activate transcription. We have demonstrated that
both mutants affect protein structure leading to compound effects of
reduced nuclear import and reduced DNA binding with consequent
reduction of transcriptional activation. Thus, CD/SRA1 arises in these
patients from a failure to properly activate transcription of target
genes during bone and testis formation.
Patients Reports--
Patient 51 was a female infant weighing
3080 g with classic CD. She died 1 day postnatal. The head showed
micrognathia, with a small mouth and elongated dome-shaped tongue,
flat nasal bridge, mild hypertelorism, and slightly low set ears. There
was disproportionate shortness of the limbs most obvious in the lower
limbs, which also showed symmetrical anterior bowing of the tibiae,
pretibial dimples, and talipes equinovarus. There was a cleft palate
involving the soft and posterior part of the hard palate. The heart was not enlarged and showed atrial situs solitus with concordant
atrioventricular and ventriculo-arterial connections. There was bowing
of both femora and tibia convexed laterally. Epiphyseal centers for the lower end of the femur and upper end of the tibiae were absent. The
tibia showed anterior bowing at the junction of the middle and lower
third of the shaft, and there were bilaterally dislocated hips and
abnormal ischial bones. There was a delay in ossification of the
epiphyseal centers, diagnostic of campomelic dwarfism. The presence of
ovarian tissue was confirmed, and numerous germ cells were seen. The
long bones showed abnormal ossification with some irregularity of
endochondral ossification. The cortical bone on the posterior aspect of
the shaft was thickened.
Patient 61 is a 46, XY female with a milder form of CD. At present, she
is 19 years of age and is assisted with mechanical ventilation. This
patient was born to healthy non-consanguineous parents at 39 weeks of
gestation. Physical examination showed flat face with prominent
forehead, cleft palate, and clubfeet. Bone survey revealed bowing of
the femurs and tibia, as well as slim, poorly developed bones and
osseous immaturity. External genitalia were feminized with mild
clitoromegaly. At 2 years of age, a human chorionic gonadotropin test
yielded no testosterone response, and a human menopause gonadotropin
test gave no estradiol response. A gonadotropin-releasing hormone test
showed hyperresponses of luteinizing hormone (7.2 Polymerase Chain Reaction Amplification, SSCP, and DNA
Sequencing--
To screen for the mutation, the entire SOX9 open
reading frame was amplified from genomic DNA from blood lymphocytes by
polymerase chain reaction and analyzed by SSCP as described previously
(24).
Molecular Modeling--
Homology modeling was used to generate
model structures of SOX9 using the NMR structure of SRY as described
previously (27). Molecules were rendered using the Molecular
Simulations Inc. software WebLabViewer.
Mutagenesis--
The CD mutations were introduced into
SOX9 using the pAlter Mutagenesis kit (Promega) according to
the manufacturer's instructions using the following
oligonucleotides: F154L,
5'-AGCGGGAGGCGAGAAGCGgCCCTTGGTGGAGAG-3'; A158T,
5'-CGCCCCTTCGTGGAGGAGACGGAGCGGCTGCGCGTGCAG-3'.
pAlter-SOX9 was subsequently digested with
EcoRI and XhoI, and the mutant cDNAs were
subcloned between the EcoRI and XhoI sites in
pcDNA3 for transient transfection in cultured cells and
in vitro production of protein. pAlterSOX9
mutants were also digested with BssHII and SacII,
and the 125-base pair fragment was inserted into the BssHI/SacII sites in the pT7SOX9HMGbox
expression plasmid (27).
Production of Mutant and Wild Type SOX9 HMG
Domains--
Recombinant SOX9 HMG protein (amino acids 101-184) was
expressed and purified from Escherichia coli as described
(29) with a modification to the protocol whereby SOX9 HMG protein was
extracted by sonication from PBS-washed cell pellets in 100 ml of HEDA
buffer (50 mM HEPES, pH 7.9, 1 mM
dithiothreitol, 1 mM EDTA, 50 µM
4-(2-aminoethyl)benzenesulfonyl fluoride). The sample was then
brought to a final concentration of 450 mM NaCl and
mixed with a 0.1 volume of 50% DEAE-Sephadex equilibrated in HEDA
buffer, 450 mM NaCl for 10 min at 4 °C. Following centrifugation (Sorvall RC5B, GS3 rotor; 6000 × g, 10 min, 4 °C), the salt concentration of the supernatant was reduced to
<0.2 M by diluting the sample volume 2.5-fold with HEDA
buffer, and the supernatant was filtered, under pressure, through a
0.45-µm membrane. The sample was injected onto a 10-ml
SP-Sepharose column pre-equilibrated in HEDA buffer containing 200 mM NaCl. Bound proteins were eluted over 40 min with
a salt gradient of HEDA buffer containing 200-1000 mM
NaCl, and 5-ml fractions were collected. SOX9 HMG elutes at
about 0.7 M NaCl containing fractions >90% SOX9
HMG protein. SOX9 HMG protein was desalted and concentrated using
Amicron Centriprep 3 cartridges. Protein concentrations were determined
against Bradford assay reagent kit (Bio-Rad) with bovine serum albumin
as a standard.
Tryptophan Fluorescence Spectroscopy--
Fluorescence spectra
were recorded on a SPEX Fluorolog-
Acrylamide quenching was performed using an excitation wavelength of
295 nm to avoid tyrosine excitation and distortion by acrylamide.
10-µl aliquots of 4 M acrylamide were added successively to 400 µl of a 2 µM protein sample, and the
fluorescence intensity was recorded at 350 nm with a PerkinElmer Life
Science LS-5 spectrofluorometer. The fluorescence was corrected for
dilution and inner-filtering by acrylamide (30, 32).
Circular Dichroism Spectroscopy--
The circular dichroism of
SOX-9 and its mutants were recorded at 222 nm using an AVIV model 62DS
spectrometer with a spectral bandwidth of 2 nm. The sample temperature
was controlled electronically with a Peltier device.
Production of Mutant and Wild Type Full-length
SOX9--
Full-length SOX9 protein was produced in vitro by
coupled transcription and translation of SOX9 (wild type and mutants)
in pcDNA3, using a TNT kit (Promega), with incorporation
of [ Cell Types and Culture and Transient Transfections--
COS-7
cells were cultured as a monolayer in RPMI 1640, supplemented with 1%
(v/v) penicillin/streptomycin, 1% L-glutamine, and 10%
(v/v) fetal calf serum, at 37 °C under 5% CO2.
COS-7 cells were transfected by DEAE-dextran-assisted electroporation
(33). Transactivation by SOX9 was measured in transfection assays,
using the reporter plasmid, pS10E1bCAT, in which
the CAT gene is under the control of the
E1b promoter, downstream of 10 SOX core-binding sites
(AACAAT). Cells (1 × 106) in log growth phase were
transfected with 1 µg of pS10 E1bCAT, 26 ng of
pcDNA3 or pcDNA3-SOX9 (wild type or
mutant), and 20 ng of pCMV-lac, in a volume of 600 ml of RPMI 1640 containing 10 mg/ml DEAE-dextran. Pulse conditions were 960 microfarads
and 250 mV using a Gene Pulser apparatus (Bio-Rad). Cells from each transfection were seeded into two flasks after addition of 6 ml of RPMI
and were grown for 48 h before being harvested. Protein concentrations, in cell lysates, were determined by Bradford assay. CAT
expression was determined by enzyme-linked immunosorbent assay, using a
CAT enzyme-linked immunosorbent assay kit (Roche Molecular Biochemicals). To correct for varying transfection efficiencies, Immunohistochemistry--
COS-7 cells were transiently
transfected with pcDNA3-SOX9 or mutant using
LipofectAMINE (Life Technologies, Inc.) according to the
manufacturer's instructions. For SOX9 staining, COS-7 cells grown in
8-well Chamber slides (Nunc) were fixed in 5% paraformaldehyde/PBS for
30 min at room temperature and permeabilized with 0.5% Triton X-100
(ICN) in PBS for 5 min at room temperature. Cells were than incubated
for 30 min with goat or horse serum in a humidified atmosphere. Cells
were than incubated with specific polyclonal antibody anti-SOX9 (9) or
anti-hemagglutinin (HA) antibody. Slides were washed three times (5 min
each) in PBS and incubated for 90 min at room temperature with
fluorescein-conjugated anti-rabbit antibody (dilution 1:500, anti-SOX9
from Sigma) or fluorescein-conjugated anti-mouse antibody, dilution
1:500 (anti-HA from Sigma). After three washes in PBS, coverslips were
mounted in glass slides with buffered glycerol (containing 1:2000
dilution of TO-PRO3 (Molecular Probes) to detect nuclei of cells) and
viewed under the Leica fluorescence microscope using a fluorescein
isothiocyanate filter, rhodamine filter, or both. Cells were
photographed using slide film (Eastman Kodak Co.) in a camera (Leica)
at × 20 and 40 magnification. Quantitation of nuclear import,
confocal laser scanning microscopy (MRC-500, Bio-Rad) was performed as
described (34).
Importin ELISA-binding Assays--
An ELISA-based assay was used
to examine the binding affinities of mouse importin- Electrophoretic Mobility Shift Assays--
Oligonucleotide
probes were synthesized on an Applied Biosystems 394 DNA/RNA
synthesizer. The sequences of the upper strands are given below. S9WT
sequence is
GGGTTAACAGAACAATGGAATCTGGTAGA. The high affinity SOX9-binding site is shown in bold. It consists of
the high affinity SOX-binding site (SOXCON) flanked by four residues
that enhance binding of SOX9 (underlined) (29). To prepare probes,
complementary oligonucleotides were annealed and radiolabeled by
end-filling with Superscript reverse transcriptase in the presence of
[ Circular Permutation Assay--
Pairs of oligonucleotides
bearing SOXCON (GGGTTAACAGAACAATGGAATCTGGTAGA) were annealed
to its complement oligonucleotide. The SOX9 high affinity-binding site
is shown in bold. pBEND2-SOXCON was created by insertion of
these linkers between the XbaI and SalI sites of
pBEND2 (36). Six circularly permuted probes bearing the
binding sites were isolated by digestion of these plasmids with
BglII (A), ClaI (B),
XhoI (C), EcoRV (D),
StuI (E), and BamHI (F) and
excision of the bands after agarose gel electrophoresis. The probes
were then treated with shrimp alkaline phosphatase and labeled with
[ Detection of Novel SOX9 Mutations in Two CD
Patients--
Analysis of the SOX9 open reading frame from
two CD/SRA1 patients using SSCP and subsequent DNA sequencing
identified two novel missense mutations (F154L and A158T) in the SOX9
HMG domain from two patients (Fig.
1A; see Table I for details).
Both patients carried the mutation on one allele
only, the other showing wild type DNA
sequence, indicating that the mutations were heterozygous.
Structure of SOX9 HMG Domain--
According to our model of SOX9
HMG domain (27), the F154L and A158T mutations substitute amino acids
on helix 3, which are predicted to be involved in maintaining the
hydrophobic core as both protrude into it (Fig. 1C). In
addition, amino acid sequence alignments of SOX9 HMG domain with SOX of
other groups show that amino acids 154 and 158 are highly conserved
(Fig. 1D). Thus, it is possible that F154L and A158T
mutations destabilize the hydrophobic core and alter the relationship
between the second and third helix leading to perturbations in the
structure of the SOX9 HMG box that may alter its biochemical properties.
Fluorescence Properties--
Changes in tryptophan fluorescence
from proteins are sensitive to the environment about the indole
chromophore and can provide information concerning changes in protein
structure and dynamics. We have shown previously that the fluorescence
from the HMG domain of SRY is sensitive to changes in local environment
about the tryptophan residues and undergoes shifts to distinct
wavelength and emission maximum upon DNA binding or calmodulin binding
when compared with the free HMG domain (31). Therefore, we measured the
tryptophan fluorescence of wild type and mutant SOX9 HMG domains. SOX9
HMG domains were expressed in E. coli bacteria
and purified by ion exchange chromatography to approximately
>90% purity by SDS-PAGE analysis (Fig.
2A). Table
II shows a comparison of three fluorescence parameters that report on the tryptophan
micropolarity (wavelength maximum), the tryptophan dynamics
(anisotropy), and the accessibility to solvent (acrylamide
accessibility). The physical extremes of these parameters correspond to
tryptophan environments that range from being non-polar to polar
(320-330 to 355 nm), mobile to immobile (<0.05 to 0.24), and
accessible to shielded (25 to <1
M Circular Dichroism--
The circular dichroism ellipticity at 222 nm is often used as an indicator of helicity in proteins and, when
combined with measurements over a range of temperatures, can yield
insight into protein conformational and thermal stability.
Table III summarizes the relative CD at
222 nm of wild type and mutant SOX9 HMG domain over a range of
temperatures. Fig. 2B shows the corresponding thermal melt
curves. Two points are of particular note. First, mutations of the SOX9
HMG domain cause a decrease in the level of (helical) secondary
structure at all temperatures investigated, as indicated by the
increased ellipticity at 222 nm of both A158T and F154L, compared with
the wild type protein. Second, the CD melt curves of all three
proteins, when normalized to an apparent fraction unfolded scale, are
superimposable which implies their folded domains have similar
stabilities to heat denaturation over the temperatures studied (Fig.
2B).
Nuclear Import and Recognition of SOX9 by Importins--
To
investigate the properties of mutant SOX9 in cultured cells, mammalian
expression plasmids encoding wild type and mutant full-length SOX9 were
constructed. SDS-PAGE analysis shows that the full-length mutant SOX9
proteins were translated efficiently from pcDNA3 plasmids in rabbit
reticulocyte lysate system (Fig. 3A). SOX9 carries signals for
nuclear import at each end of its HMG domain (28). NLSs tend to be
amphipathic helices, and so the function of the SOX9 NLSs could be
perturbed by structural changes (loss of helicity) in the HMG domain.
To assess the effect of SOX9 mutations upon nuclear import, full-length
wild type and mutant SOX9 plasmids were transiently transfected into
COS-7 cells, and the subcellular localization of SOX9 was determined
24 h after transfection using indirect immunofluorescence and
confocal laser scanning microscopy and quantitated using image analysis
(Fig. 3B). Wild type SOX9 efficiently accumulated in the
nucleus (ratio of accumulation of SOX9 fluorescence in the nucleus
relative to the cytoplasm
NLSs are conventionally recognized by the nuclear import receptor, a
heterodimer of importin (karyopherin)- DNA Binding and DNA Bending--
SOX9 encoded by some CD patients
showed reduced DNA binding activity consistent with the DNA binding
ability of SOX9 being essential for its function as a transcription
factor. The ability of the mutants to bind DNA, relative to wild type,
was measured. DNA concentrations were varied, and SOX9-bound
versus free DNA was quantitated from electrophoretic
mobility shift gels (Fig. 4A)
(29). DNA probe SOX9CON bears the high affinity SOX9-binding site
selected in vitro (AGAACAATGG) which consists of SOX
consensus motif (A/T)(A/T)CAA(A/T) flanked on either side by the two
bases specifically preferred by SOX9 (29). The dissociation constant (Kd) was calculated for wild type and mutant
SOX9-DNA complexes, and Scatchard plots were drawn (Fig. 4B;
Table V). Wild type SOX9 HMG gave a
Kd of 12.6 nM, consistent with the
published value of 12.4 nM (29). F154L by comparison gave Kd of 244 nM, a reduction to 5% of wild
type SOX9 DNA binding affinity. A158T is less affected with a
Kd of 76 nM, a reduction to 16.6% of
wild type SOX9 DNA binding affinity.
Certain point mutations in the HMG domain of SRY in patients with XY
gonadal dysgenesis alter the DNA bending properties of the protein (8).
Since DNA bending is also likely to be important for SOX9 function, we
set out to determine the bend angles induced upon binding of the wild
type and mutant HMG domains to SOX9CON DNA probe. A circular
permutation assay was used to determine the bend angle induced by SOX9
HMG (Fig. 5). Wild type deflected the
linear DNA probe SOX9CON by 59 ± 0.5°. Differences
between our results and those published (39-41) could be due to slight differences in assay conditions, as have been observed for SRY. Both
the mutants and wild type SOX9 show no significant differences in their
ability to bend DNA with both mutants also bending DNA 59 ± 0.5° from linearity. Thus, the F154L and A158T mutations did not
appear to alter the DNA bending properties of SOX9.
Transactivation Properties in Cultured Cells--
In order
to determine whether the two mutations SOX9F154L and SOX9A158T had
altered transcriptional activity, pcDNA3-SOX9F154L and
pcDNA3-SOX9A158T plasmids were transiently transfected
with pS10E1bCAT into COS-7 cells. Transcriptional activity
of both mutant proteins was significantly lower than wild type SOX9. In COS-7 cells transfected with the reporter construct pS10E1bCAT and pcDNA3-SOX9F154L, expression of the
CAT reporter gene was 26% of wild type SOX9 activity (Fig.
6). In COS-7 cells transfected with the
reporter construct and pcDNA3-SOX9A158T, expression of the CAT reporter gene was 62% of wild type SOX9 (Fig. 6;
Table VI). Quantities of
SOX9-transfected plasmids were in the linear response range
(data not shown).
In this study, we report the identification of the novel amino
acid substitution mutations F154L and A158T in the SOX9 HMG domain of
two patients with campomelic dysplasia, the former an XX female and the
latter a sex-reversed XY female. Fig. 1B shows the positions
of these substitutions on the SOX9 open reading frame together with
those of previously reported mutations. Apart from the fact that all
known missense mutations occur in the HMG domain, no correlation seems
to be emerging between the position of the mutations and their clinical
severity and associated sex reversal.
Based upon our molecular model of SOX9 (27), we postulated that
Phe154 and Ala158 form part of a
hydrophobic core region and would play a role in stabilizing the
three-dimensional alignment of the three helices of the HMG domain. The
substitution of a phenylalanine by a leucine in mutant F154L may have
several consequences including an alteration of hydrophobic packing due
to the replacement of a bulkier amino acid by a smaller one (39), a
loss of aromatic-aromatic interactions (40-43), or a decrease in
helicity due to alterations of phenylalanine-side chain
interactions between amino acids proximal to helix 3 (44). The
replacement of an alanine by a threonine in mutant A158T substitutes a
small non-polar amino acid for a big relatively non-polar amino acid
and thus would be expected to affect hydrophobic interactions in this
region of the protein. However, the fluorescence studies did not
demonstrate significant changes in tertiary structure. The mutations
would appear not to perturb the environment or tertiary structure
(relative orientation of the helices) as probed by the tryptophan
residues of the hydrophobic core, nor does it affect the stability of
the (residual) folded structure of the mutants as compared with the
wild type protein. This could suggest functional redundancy in amino
acids that form the hydrophobic core.
In contrast, our circular dichroism results suggest that the main
effect of mutation at Phe154 and Ala158 is upon
loss of secondary structure, mainly in helix 3. Both SOX9 mutations are
located close to helix 1/helix 2 tryptophan residues. In the related
Sox5 protein, the concept of "multidomain unfolding" has
been explored whereby unfolding of helix 1/helix 2 arm leads to large
(15 nm) changes in tryptophan fluorescence (45). Thus a complete loss
of structure in the helix 1/helix 2 wing is an unlikely consequence of
the mutations since the tryptophan fluorescence properties of the two
mutant SOX9 proteins are largely unaffected, but small changes could be
through "local effects" of the substitutions. This leaves the
possibility that helix 3 itself is perturbed in local structure.
Threonine is known to cause loss of secondary structure (46) and to
bend Helix 3 of the SOX9 HMG domain possesses a functional NLS, as does
helix 1 (28) (Fig. 1D). We show that SOX9 is recognized by
the nuclear transport receptor importin- Substitutions at the two positions in SOX9 studied here have also been
reported at the corresponding positions in the HMG domain of SRY in two
XY gonadal dysgenesis patients. The first example is SRY-A113T,
analogous to SOX9-A158T, which showed reduced DNA binding like the
SOX9-A158T mutant but also showed altered DNA bending
(48).3 This suggests that
altering the secondary structure in this region of the HMG domain of
SRY and SOX9 (which show 70% amino acid similarity) has different
consequences. Thus DNA bending by wild type SRY and SOX9 HMG domains is
not identical, despite their ability to bend DNA of the same sequence
to the same angle (27, 29). Key determinants of DNA bending appear to
reside on helix 1 consistent with the observation that helix 1/2 is
unperturbed and DNA bending is normal in both SOX9 mutants in this
study. Helix 1/2 wing contributes two key helix 1 amino acids,
Met111 (Ile68 in SRY), which acts as a wedge
intercalator and adjacent Met107 (Met64 in SRY;
two sex-reversing SRY mutations at Met64 alter bend angle
(8)),3 which interacts with the DNA backbone at the site of
the bend. The second example is the SRY-F109S substitution in an XY
gonadal dysgenesis patient, which corresponds to SOX9-F154L and is a
familial mutation inherited by the fertile father (49). The structure of SRY shows that the Phe109 is buried within the
hydrophobic core and packs against Ala111,
Val114, and Trp115 of helix 1 and
Phe155 of helix 2 (SOX9 numbering; Fig. 1C) and
might be expected to affect protein stability. Although SRY-F109S
protein showed no significant change in DNA binding affinity compared
with wild type (49), the substitution of Phe for Leu in SOX9 caused a 20-fold reduction in DNA binding. The simplest explanation is that
serine substitution would be less disruptive to the hydrophobic core
than leucine substitution in either context.
This study presents data for the first time on the effect of point
mutations in CD upon transactivation activity in cultured cells and
allows us to correlate this with DNA binding activity in
vitro. In the A158T mutant, a 6-fold loss of DNA binding activity together with a 2-fold loss of nuclear import led to only a 26% loss
of transcriptional activation. Similarly, in the F154L mutant, a
20-fold loss of DNA binding activity led to only a 62% loss of
transcriptional activation activity. Our binary in vitro
system is simplistic given that SOX9 acts in the context of a
multiprotein complex in vivo. During testis formation,
SOX9-SF1 and WT1-SF1 are required on the MIS promoter (11),
and the Sox5/Sox6 heterodimers are required for maximal activation of
the Col2a1 promoter (18). Furthermore, reduced DNA binding
affinity may still permit transient occupancy of a SOX9-binding site by
SOX9 in vivo at levels sufficient to activate transcription
once bound, provided the correct DNA architecture is established (50,
51). Also, it might be that other functions of the HMG domain, for
example interactions with co-activators, are at play. Our data are
consistent with that for yeast ROX1, the only other HMG domain protein
for which in vitro/in vivo correlations have been
reported. In ROX1, substitutions causing a large reduction in DNA
binding activity in vitro produce a small effect upon
ANB1 repressor activity in vivo (52). For example
the analogous change to SOX9 A158T in ROX1 affects DNA binding 10-fold
and repression in vivo 4-fold. In ROX1 Phe154 is
Trp and a substitution to Leu affects DNA binding 1000-fold but
repression only 50-fold. Thus a reduction in DNA binding in vitro produces only a small effect in vivo, but this is
presumably sufficient to account for the phenotypic effects. On this
basis, small changes in DNA binding activity of SOX9 mutants may show undetectable changes in transactivation and lead to wild type phenotype. In SRY, small changes in DNA binding activity with partial
penetrance of SRY were observed to occur in familial cases, i.e. when a weak allele is inherited by a fertile father (7, 49). However small changes in SOX9 DNA binding activity in
vitro do not seem to correlate with milder symptoms, in these
cases it could be that alterations of non-DNA binding functions of the HMG domain underlie the defect. Our data show that A154T mutant has
62% of wild type activation function in cultured cells. Given that
this observation reflects the situation in vivo in CD/SRA1 where one allele is mutant for SOX9 and the other is wild type, our
study raises the possibility that a high level of SOX9 transactivation activity is normally required for proper testis and bone formation. It
is likely that interactions with transcriptional co-activators or
components of the basal transcriptional machinery may attenuate the
effect of mutation.
-helicity within their high
mobility group domain, whereas tertiary structure is essentially
maintained as judged by fluorescence spectroscopy. In cultured cells,
strictly nuclear localization was observed for wild type SOX9 and the
F154L mutant; however, the A158T mutant showed a 2-fold reduction in
nuclear import efficiency. Importin-
was demonstrated to be the
nuclear transport receptor recognized by SOX9, with both mutant
proteins binding importin-
with wild type affinity. Whereas DNA
bending was unaffected, DNA binding was drastically reduced in both
mutants (to 5% of wild type activity in F154L, 17% in A158T). Despite
this large effect, transcriptional activation in cultured cells was
only reduced to 26% in F154L and 62% in A158T of wild type activity,
suggesting that a small loss of SOX9 transactivation activity could be
sufficient to disrupt proper regulation of target genes during bone and
testis formation. Thus, clinically relevant mutations of
SOX9 affect protein structure leading to compound effects
of reduced nuclear import and reduced DNA binding, the net effect being
loss of transcriptional activation.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-helices that come together in an
L-shape in which the short arm is formed by helices 1 and 2 and the
long arm by helix 3 and the N-terminal strand. The concave surface of
the "L" contacts the minor groove of the DNA. A number of
hydrophobic amino acids from each helix pack together to form a
"hydrophobic core" that is thought to stabilize the helices. We
previously constructed a model of the SOX9 HMG domain (27), based on
the solution structure of the SRY HMG domain, and we observed that most
clinical mutations of SOX9 and SRY lie at or near the DNA-binding
surface. Here we describe two novel mutations, A154L and A158T, that
substitute amino acids within the hydrophobic core and raise the
possibility that these residues contribute to the conformation of the
HMG domain. Based on our model, these amino acids on helix 3 do not
directly bind to DNA, rather they may destabilize the secondary and/or
tertiary structure of the HMG domain. This in turn may affect DNA
binding and/or DNA bending function of the HMG domain. Also, a signal
for nuclear import of SOX9 is located in helix 3 raising the
possibility that nuclear import could be affected (28). This nuclear
localization signal (NLS) is likely recognized by one of the importins
that dock NLS-containing proteins at the nuclear pore complex. We have investigated which components of the nuclear transport machinery normally recognize SOX9 and show that importin-
strongly interacts with SOX9.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
66.5 IU/liter) and follicle-stimulating hormone (11.3
80.2 IU/liter).
2 frequency domain
spectrofluorometer. Excitation of tryptophan was accomplished using
vertically polarized light at 295 nm from a 450-watt xenon lamp. The
emission was observed through a polarizer oriented at the magic
angle (54.7o), and spectra were measured in the wavelength
range of 300-500 nm. The spectral band pass of excitation and emission
was 5 nm. 500-µl cuvettes were used with a protein concentration of 2 µM. Spectra were fully corrected for the wavelength
response of the detection system. The cell block was maintained at
20 °C with a circulating water bath (30, 31).
-35S]methionine.
-galactosidase levels were assayed, and CAT levels were normalized for
-galactosidase expression.
-Galactosidase expression was assayed using the
-galactosidase enzyme assay system (Promega).
and
importin-
-glutathione S-transferase (GST) fusion proteins
as described previously (34). 96-Well microtiter plates were coated
with bacterially expressed and purified HMG domains and incubated
overnight at 4 °C. After blocking with bovine serum albumin, the
protein was hybridized to increasing amounts of importin-
-GST,
importin-
-GST, or precomplexed importin-
/
-GST and incubated
for 16 h at 4 °C. Bound importin was detected using goat
anti-GST and anti-goat IgG, alkaline phosphatase-conjugated antibodies.
After the addition of the colorimetric substrate
p-nitrophenyl phosphate, A405 was measured at
5-min intervals for 90 min using a microplate reader (Molecular
devices, Sunnyvale, CA), and values were corrected by subtracting
absorbances both at 0 min and in wells incubated without importin.
-32P]dCTP and purified on Bio-Gel P4 spin columns.
E. coli cell lysates containing SOX9 HMG domain (0.25 nM) were mixed with
-32P-labeled probe in a
total volume of 16 ml of binding buffer (35) and kept on ice for 15 min
before electrophoresis. Protein-DNA complexes were resolved from free
DNA on non-denaturing 6% polyacrylamide gels (40:1 (w/w)
acrylamide/bisacrylamide) in 0.5 × TBE for 3.5 h at 10 V/cm. Prior to sample loading, the gel was pre-run for 2 h at 150 V. Shifted and free probe was quantitated by PhosphorImager analysis.
-32P]ATP using T4 polynucleotide kinase. Probes
(0.2-0.8 ng) were mixed with extract containing 0.2 µg of wild type
~2 µg of mutant SOX9 HMG domain in binding buffer (35), in a total
volume of 16 µl, and kept for 20 min on ice. Products were resolved
by electrophoresis through 6.5% polyacrylamide non-denaturing gels
(40:1 (w/w) acrylamide/bisacrylamide) as described above. Bend
parameters were calculated as described previously (37). Gels were
exposed to PhosphorImaging plates and developed on a Fujix Bas 2000.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (67K):
[in a new window]
Fig. 1.
Detection of two novel SOX9 mutations
in patients with CD/SRA1. A, SSCP assay of DNA from
patients 51 and 61; in each case the band that differs between the
mutant and wild type alleles is indicated with an arrow.
Controls include DNA amplified from two normal individuals. DNA
sequence analysis of the abnormally migrating bands shows the codon
change TTC to TTG specifying a Phe154 to Leu amino acid
substitution in patient 51 and codon change GCG to ACG specifying a
Ala158 to Thr amino acid substitution in patient 61. B, diagram of the entire SOX9 open reading frame showing the
different domains of the protein and the missense mutations that have
been identified in patients with CD. SOX9 is a 509-amino
acid-long protein that has three notable features as follows: an HMG
box 100 amino acids from the N terminus; a PQA (residues 339-379); and
a PQS-rich (residues 386-509) domain at the C terminus of the protein.
Mutations identified in XY females (i.e. showing autosomal
sex reversal, SRA1 phenotype) are indicated as circles
below and those in XX females (F) or XY males
(M) above. Mutations investigated in the present
study are indicated with filled circles. C, the
HMG box of SOX9 is an 80-amino acid DNA binding domain, consisting of
three
-helices that form an L-conformation. The HMG box has a highly
hydrophobic core formed by amino acids mainly on the first and second
helix, and this core maintains the angles between the helices. The
hydrophobic core is believed to be maintained by the orthogonal packing
of 11 amino acids, mainly on helix 1 and 2 with contributions from
Phe154 and Ala158 (underlined) from
helix 3. This representation of SOX9 HMG is in a DNA-bound conformation
showing the DNA severely bent and unwound by SOX9. The atomic
coordinates (code BNL-27758 for the model of the wild type SOX9
HMG domain model are available in the Protein Data Bank, Research
laboratory for Structural Bioinformatics, Rutgers University, New
Brunswick, NJ). D, an amino acid sequence alignment of SOX9
HMG domain with selected SOX proteins, representing each subgroup,
showing high conservation of both Phe154 and
Ala158 positions. Regions shaded show the N- and
C-terminal nuclear localization signals. Boxed regions
correspond to the positions of the three helices and loops of the SOX9
HMG domain.
Missense CD mutations analyzed in this study
1), respectively. Table II shows
that the SOX9 HMG tryptophan fluorescence is characterized by a
relatively non-polar environment (340 nm), a moderate accessibility to
acrylamide (10 M
1), and is
restricted in its mobility (0.125). The A158T mutation produces no
detectable alteration in the micropolarity or mobility of the
tryptophan residues, and a 10% decrease in accessibility to acrylamide
compared with wild type (a 4% change compared with fully
accessible/shielded). The F154L mutation changes all three tryptophan fluorescence parameters. Compared with the wild type protein, the tryptophan micropolarity (339 nm) and mobility (0.131) undergo a slight decrease, whereas the accessibility to acrylamide increases (11 M
1). As for the
A158T mutation, the change in these parameters represents a fractional
change of less than 5% compared with the full range of parameter
space.

View larger version (17K):
[in a new window]
Fig. 2.
Circular dichroism analysis of normal and
mutant HMG domain structure. A, SDS-PAGE analysis of
E. coli recombinant wild type (WT) and mutant
SOX9 HMG domains produced in E. coli. Cell lysates before
(
) and after (+) ion exchange chromatography were resolved on a
10-20% polyacrylamide gradient gel at 20 V/cm for 180 min and stained
with Coomassie Brilliant Blue. The position of the SOX9 HMG domain and
molecular size markers in kilodaltons are indicated on the
left. B, the temperature dependence of the
relative ellipticity at 222 nm of SOX9 HMG domains (filled
circles) and SOX9 mutants, A158T (unfilled squares),
F154L (filled squares). C, thermal denaturation
curves of SOX9 and mutants. The apparent fraction unfolded protein is
plotted against temperature. Symbols as for Fig. 2B.
Tryptophan fluorescence parameters of SOX9 and single substitution
mutants
Thermal stability and helicity of SOX9 and mutants
Fn/c of 30) as did
the F154L mutant, but the F158T mutant showed a significant
(p = 0.0316) reduction of nuclear accumulation of
approximately 2-fold (Fn/c of 13).

View larger version (34K):
[in a new window]
Fig. 3.
Nuclear accumulation and importin binding of
full-length wild type and mutant SOX9. A, autoradiography of
SDS-PAGE of wild type and missense mutations of SOX9 expressed in
vitro in rabbit reticulocyte lysate. Molecular size markers in
kilodaltons are indicated on the left. B,
plasmids for mammalian cell expression of hemagglutinin (HA)
epitope-tagged SOX9, pcDNA3-HA-SOX9,
pcDNA3-HA-SOX9A158T and
pcDNA3-HA-SOX9F154L were transfected into COS-7
and SOX9 protein detected by indirect immunofluorescence, using rabbit
anti-HA as the first antibody and fluorescein isothiocyanate-conjugated
goat anti-rabbit antibody as the second antibody. Fn/c
refers to the ratio between nuclear (Fn) and cytoplasmic
fluorescence (Fc). Each point represents the average of
greater than 19 separate measurements of each of Fn, Fc, and
autofluorescence. A one-way analysis of variance revealed a significant
difference between the mean Fn/c values for wild type and
the A158T mutant, p < 0.032. C, Binding
curves of SOX9 HMG domains with importins. ELISA microtiter plates were
coated with SOX9 HMG box or mutant as indicated and incubated with
increasing concentrations of mouse importin subunits. Data are fitted
for the function B(x) = Bmax (1
e
kB), where x is the
concentrations of importin and B is the amount of importin
bound. The results are from a single experiment performed in triplicate
(see Table IV for Kd values, representing the
importin concentration yielding half-maximal binding, from pooled
data).
/
subunits (see Ref. 38 for
review). The HMG domain of SRY is recognized directly by importin-
,
independently of importin-
, via the NLS at the C-terminal end of
helix 3.2 This NLS sequence
is highly conserved in all SOX proteins, so it seemed likely that
importin-
would interact with SOX9. To test this possibility, we
investigated, by ELISA, the interaction of the SOX9 HMG box with
importin-
, importin-
, and the heterodimer importin-
/
. SOX9
HMG domain is recognized more strongly by importin-
(Kd of 1.7) compared with importin-
(55 nM) (Fig. 3C; Table IV) consistent with the results
obtained for SRY.2 No significant differences in
importin-
binding were detected for the SOX9 mutants compared
with wild type SOX9 HMG box suggesting that the decrease in nuclear
accumulation of mutant A158T is not due to defects in importin-
binding (Fig. 3C).
NLS binding parameters of SOX9 derivatives as measured using an
ELISA-based binding assay
/
to
SOX9 wt represent the mean ± S.E.M. (n in
parentheses).

View larger version (39K):
[in a new window]
Fig. 4.
Scatchard analysis of the equilibrium DNA
binding of wild type and mutant SOX9 HMG domains. A,
binding reactions containing a fixed amount of SOX9 HMG domain (0.25 nM) and increasing concentrations of DNA probe (10-150
nM, right to left) were resolved by
non-denaturing gel electrophoresis and bound and free DNA probe
quantitated from three experiments performed in duplicate. An
electrophoretic mobility shift assay is representative of one
experiment shown. B, Scatchard analysis of the equilibrium
binding of SOX9 HMG domain to DNA probe SOX9CON. The points plotted are
the mean of duplicate data points from one experiment, see Table V for
pooled data.
DNA binding activity of wild type and mutant SOX9

View larger version (28K):
[in a new window]
Fig. 5.
DNA bending by wild type and F154L or A158T
mutant HMG domains. Circularly permutated probes were labeled with
32P and incubated with ~0.2 µg of F154L, 0.2 µg of
A158T HMG domain, or 0.02 µg of wild type HMG domain. Bend angles
were estimated as described previously (48). The probe names
(A (BglII), B (ClaI),
C (XhoI), D (EcoRV),
E (StuI), and G (BamHI))
relate to the position of the SOX-binding site following restriction
digestion of a linear DNA fragment shown at top comprising a
tandem multiple cloning site with a central SOX9 DNA-binding site
(30).

View larger version (11K):
[in a new window]
Fig. 6.
Transactivation of full-length wild type and
mutant SOX9. Transcriptional activity of SOX9 and mutants was
measured by determination of CAT expression in lysates of COS-7 cells
co-transfected with pcDNA3-SOX9 (and missense mutants)
and the reporter plasmid pS10E1bCAT. pCMV-lac
was co-transfected, and
-galactosidase activity was assayed to
account for variations in transfection efficiency. A one-way analysis
of variance revealed a significant difference between the mean levels
of CAT/unit
-galactosidase for the different DNA constructs
(F (2, 15) = 22.962, p < 0.001).
Comparison with wild type SOX9 shows a significant decrease in
transcriptional activity for both mutants (**, p < 0.01; ***, p < 0.001).
Transactivation of wild type and mutant SOX9
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-helices (47). Furthermore, thermally induced unfolding of
helix 3 as a separate domain from helix 1 and helix 2 has been observed
in the HMG domain of Sox5 (45).
and not by the more widely
reported NLS receptor, importin-
. Given that the NLSs are highly
conserved among SOX proteins (shaded in Fig. 1D),
we predict that all SOX proteins utilize an importin-
-mediated
nuclear import pathway. The NLS located at the end of helix 3 is a
conventional basic amphipathic helix which, in SRY, mediates nuclear
import via direct interaction with importin-
.2 In SOX9,
the A158T mutant showed decreased nuclear accumulation. This mutation
is more proximal to the helix 3 NLS than F154L (whose nuclear import
was normal) and might disrupt the function of this NLS. However, A158T
bound with wild type affinity to importin-
suggesting that while
this recognition step is normal, other components of the
importin-
-mediated nuclear import pathway could be affected. Alternatively, the A158T mutation could indirectly affect the function
of the helix 1 NLS, whose import mechanism has not been defined, but
may involve calmodulin which has been implicated in import and which
recognizes helix 1 of SRY (31). The two NLSs appear to be able to
function independently but are close together in three-dimensional
space, and the dramatic conformational changes to SRY HMG domain that
occur upon calmodulin binding might regulate NLS activity. Further
studies are also required to elucidate the component of nuclear import
that presumably fails to recognize efficiently the A158T mutant. The
demonstration here that a mutation outside the NLS regions affects
nuclear localization raises the possibility that a large number of
SRY, SOX9, and SOX10 clinical mutations could affect nuclear import in addition to, or distinct from,
DNA binding and bending. In support of this, SRY mutation R62G, a
mutation outside the helix 3 NLS, showed decreased nuclear accumulation
and reduced importin-
binding.2
| |
ACKNOWLEDGEMENTS |
|---|
This work was initiated in the laboratory of Human Molecular Genetics in the department of Genetics at Cambridge University under the supervision of Peter Goodfellow. We thank Peter Fuller and Michael Clarkson for helpful discussion.
| |
FOOTNOTES |
|---|
* This work was supported by National Health and Medical Research Council of Australia Grant 983001.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
c Both authors contributed equally to this work.
j To whom correspondence should be addressed. Tel.: 613 9549 3244; Fax: 613 9594 6125; E-mail: vincent.harley@med.monash.edu.au.
Published, JBC Papers in Press, April 25, 2001, DOI 10.1074/jbc.M101278200
2 S. Layfield, D. A. Jans, and V. R. Harley, manuscript in preparation.
3 C. Mitchell and V. R. Harley, unpublished results.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: CD/SRA1 campomelic dysplasia/autosomal sex reversal, CAT, chloramphenicol acetyltransferase; HMG, high mobility group; SRY, sex determining region of the Y chromosome; SSCP, single strand conformation polymorphism; WT, wild type; ELISA, enzyme-linked immunosorbent assay; PBS, phosphate-buffered saline; GST, glutathione S-transferase; PAGE, polyacrylamide gel electrophoresis; NLS, nuclear localization signal; HA, hemagglutinin.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Foster, J. W., Dominguez-Steglich, M. A., Guioli, S., Kowk, G., Weller, P. A., Stevanovic, M., Weissenbach, J., Mansour, S., Young, I. D., Goodfellow, P. N., Brook, D. N., and Schafer, A. S. (1994) Nature 372, 525-530 |
| 2. | Wagner, T., Wirth, J., Meyer, J., Zabel, B., Held, M., Zimmer, J., Pasantes, J., Bricarelli, F. D., Keutel, J., Hustert, E., Wolf, U., Tommerup, N., Schempp, W., and Scherer, G. (1994) Cell 79, 1111-1120 |
| 3. | Lynch, S. A., Gaunt, M. L., and Minford, A. M. (1993) J. Med. Genet. 30, 683-686 |
| 4. | Schafer, A. J. (2001) in Campomelic Dysplasia/Autosomal Sex Reversal/SOX9 (Scriver , Beaudet , Valle , and Sly, eds), 8th Ed. , McGraw-Hill Inc., New York |
| 5. | Cameron, F. J., and Sinclair, A. H. (1997) Hum. Mutat. 9, 388-395 |
| 6. | Koopman, P. (1999) Cell. Mol. Life Sci. 55, 839-856 |
| 7. | Harley, V. R., Jackson, D. I., Hextall, P. J., Hawkins, J. R., Berkovitz, G. D., Sockanathan, S., Lovell-Badge, R., and Goodfellow, P. N. (1992) Science 255, 453-456 |
| 8. | Pontiggia, A., Rimini, R., Harley, V. R., Goodfellow, P. N., Lovell-Badge, R., and Bianchi, M. E. (1994) EMBO J. 13, 6115-6124 |
| 9. | Morais da Silva, S., Hacker, A., Harley, V., Goodfellow, P., Swain, A., and Lovell-Badge, R. (1996) Nat. Genet. 14, 62-68 |
| 10. | Kent, J., Wheatley, S. C., Andrews, J. E., Sinclair, A. H., and Koopman, P. (1996) Development 122, 2813-2822 |
| 11. | de Santa Barbara, P., Moniot, B., Poulat, F., and Berta, P. (2000) Dev. Dyn. 217, 293-298 |
| 12. | de Santa Barbara, P., Bonneaud, N., Boizet, B., Desclozeaux, M., Moniot, B., Sudbeck, P., Scherer, G., Poulat, F., and Berta, P. (1998) Mol. Cell. Biol. 18, 6653-6665 |
| 13. | Arango, N. A., Lovell-Badge, R., and Behringer, R. R. (1999) Cell 99, 409-419 |
| 14. | Ng, L. J., Wheatley, S., Muscat, G. E., Conway-Campbell, J., Bowles, J., Wright, E., Bell, D. M., Tam, P. P., Cheah, K. S., and Koopman, P. (1997) Dev. Biol. 183, 108-121 |
| 15. | Lefebvre, V., Huang, W., Harley, V. R., Goodfellow, P. N., and de Crombrugghe, B. (1997) Mol. Cell. Biol. 17, 2336-2346 |
| 16. | Bi, W., Deng, J. M., Zhang, Z., Behringer, R. R., and de Crombrugghe, B. (1999) Nat. Genet. 22, 85-89 |
| 17. | Lefebvre, V., and DeCrombrugghe, B. (1998) Matrix Biol. 16, 529-540 |
| 18. | Lefebvre, V., Li, P., and de Crombrugghe, B. (1998) EMBO J. 17, 5718-5733 |
| 19. | Zhao, Q., Eberspaecher, H., Lefebvre, V., and de Crombrugghe, B. (1997) Dev. Dyn. 209, 377-386 |
| 20. | Bell, D. M., Leung, K. K., Wheatley, S. C., Ng, L. J., Zhou, S., Ling, K. W., Sham, M. H., Koopman, P., Tam, P. P., and Cheah, K. S. (1997) Nat. Genet. 16, 174-178 |
| 21. | Sekiya, I., Tsuji, K., Koopman, P., Watanabe, H., Yamada, Y., Shinomiya, K., Nifuji, A., and Noda, M. (2000) J. Biol. Chem. 275, 10738-10744 |
| 22. | Bridgewater, L. C., Lefebvre, V., and DeCrombrugghe, B. (1998) J. Biol. Chem. 273, 14998-15006 |
| 23. | Meyer, J., Sudbeck, P., Held, M., Wagner, T., Schmitz, M. L., Bricarelli, F. D., Eggermont, E., Friedrich, U., Haas, O. A., Kobelt, A., Leroy, J. G., Van Maldergem, L., Michel, E., Mitulla, B., Pfeiffer, R. A., Schinzel, A., Schmidt, H., and Scherer, G. (1997) Hum. Mol. Genet. 6, 91-98 |
| 24. | Kwok, C., Weller, P. A., Guioli, S., Foster, J. W., Mansour, S., Zuffardi, O., Punnett, H. H., Dominguez Steglich, M. A., Brook, J. D., and Young, I. D. (1995) Am. J. Hum. Genet. 57, 1028-1036 |
| 25. | Foster, J. W. (1996) Acta Paediatr. Jpn. 38, 405-411 |
| 26. | Hageman, R. M., Cameron, F. J., and Sinclair, A. H. (1998) Hum. Mutat. (suppl.), 112-113 |
| 27. | McDowall, S., Argentaro, A., Ranganathan, S., Weller, P., Mertin, S., Mansour, S., Tolmie, J., and Harley, V. (1999) J. Biol. Chem. 274, 24023-24030 |
| 28. | Sudbeck, P., and Scherer, G. (1997) J. Biol. Chem. 272, 27848-27852 |
| 29. | Mertin, S., McDowall, S. G., and Harley, V. R. (1999) Nucleic Acids Res. 27, 1359-1364 |
| 30. | Clayton, A. H., and Sawyer, W. H. (1999) Biophys. J. 76, 3235-3242 |
| 31. | Harley, V. R., Lovell-Badge, R., Goodfellow, P. N., and Hextall, P. J. (1996) FEBS Lett. 391, 24-28 |
| 32. | Eftink, M. R., and Ghiron, C. A. (1976) Biochemistry 15, 672-680 |
| 33. | Gauss, G. H., and Lieber, M. R. (1992) Nucleic Acids Res. 20, 6739-6740 |
| 34. | Hubner, S., Xiao, C. Y., and Jans, D. A. (1997) J. Biol. Chem. 272, 17191-17195 |
| 35. | van de Wetering, M., Oosterwegel, M., Dooijes, D., and Clevers, H. (1991) EMBO J. 10, 123-132 |
| 36. | Kim, J., Zwieb, C., Wu, C., and Adhya, S. (1989) Gene (Amst.) 85, 15-23 |
| 37. | Thompson, J. F., and Landy, A. (1988) Nucleic Acids Res. 16, 9687-9705 |
| 38. | Jans, D. A., Xiao, C-Y., and Lam, M. H. C. (2000) Bioessays 22, 532-544 |
| 39. | Vlassi, M., Cesareni, G., and Kokkinidis, M. (1999) J. Mol. Biol. 285, 817-827 |
| 40. | Hunter, C. A., Singh, J., and Thornton, J. M. (1991) J. Mol. Biol. 218, 837-846 |
| 41. | Serrano, L., Bycroft, M., and Fersht, A. R. (1991) J. Mol. Biol. 218, 465-475 |
| 42. | Jasanoff, A., Kochoyan, M., Fraenkel, E., Lee, J. P., and Weiss, M. A. (1992) J. Mol. Biol. 225, 1035-1047 |
| 43. | Nanda, V., and Brand, L. (2000) Proteins 40, 112-125 |
| 44. | Padmanabhan, S., and Baldwin, R. L. (1994) Protein Sci. 3, 1992-1997 |
| 45. | Crane Robinson, C., Read, C. M., Cary, P. D., Driscoll, P. C., Dragan, A. I., and Privalov, P. L. (1998) J. Mol. Biol. 281, 705-717 |
| 46. | Vijayakumar, M., Qian, H., and Zhou, H. X. (1999) Proteins 34, 497-507 |
| 47. | Ballesteros, J. A., Deupi, X., Olivella, M., Haaksma, E. E., and Pardo, L. (2000) Biophys. J. 79, 2754-2760 |
| 48. | Zeng, Y. T., Ren, Z. R., Zhang, M. L., Huang, Y., Zeng, F. Y., and Huang, S. Z. (1993) J. Med. Genet. 30, 655-657 |
| 49. | Jager, R. J., Harley, V. R., Pfeiffer, R. A., Goodfellow, P. N., and Scherer, G. (1992) Hum. Genet. 90, 350-355 |
| 50. | Ferrari, S., Harley, V. R., Pontiggia, A., Goodfellow, P. N., Lovell-Badge, R., and Bianchi, M. E. (1992) EMBO J. 11, 4497-4506 |
| 51. | Giese, K., Pagel, J., and Grosschedl, R. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 3368-3372 |
| 52. | Deckert, J., Khalaf, R. A., Hwang, S. M., and Zitomer, R. S. (1999) Nucleic Acids Res. 27, 3518-326 |